Evidence map›Paper›PMID 29052513›Full record

ArticleBMC medical genomics2017

A method to reduce ancestry related germline false positives in tumor only somatic variant calling.

Rebecca F Halperin, John D Carpten, Zarko Manojlovic, Jessica Aldrich, Jonathan Keats, Sara Byron, Winnie S Liang, Megan Russell, Daniel Enriquez, Ana Claasen and 8 more

Abstract read
In one paragraph

Article in BMC medical genomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rebecca F HalperinCenter for Translational Innovation, Translational Genomics Research Institute, Phoenix, AZ, USA.
John D CarptenDepartment of Translational Genomics, University of Southern California, Los Angeles, CA, USA. carpten@usc.edu.
Zarko ManojlovicDepartment of Translational Genomics, University of Southern California, Los Angeles, CA, USA.
Jessica AldrichIntegrated Cancer Division, Translational Genomics Research Institute, Phoenix, AZ, USA.
Jonathan KeatsIntegrated Cancer Division, Translational Genomics Research Institute, Phoenix, AZ, USA.
Sara ByronCenter for Translational Innovation, Translational Genomics Research Institute, Phoenix, AZ, USA.
Winnie S LiangNeurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.
Megan RussellIntegrated Cancer Division, Translational Genomics Research Institute, Phoenix, AZ, USA.
Daniel EnriquezNeurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.
Ana ClaasenNeurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.
Irene CherniIntegrated Cancer Division, Translational Genomics Research Institute, Phoenix, AZ, USA.
Baffour AwuahKomfo Anokye Teaching Hospital, Kumasi, Ghana.
Joseph OppongKomfo Anokye Teaching Hospital, Kumasi, Ghana.
Max S WichaUniversity of Michigan, Ann Arbor, MI, USA.
Lisa A NewmanHenry Ford Health Systems, Detroit, MI, USA.
Evelyn JaiggeUniversity of Michigan, Ann Arbor, MI, USA.
Seungchan KimIntegrated Cancer Division, Translational Genomics Research Institute, Phoenix, AZ, USA.
David W CraigDepartment of Translational Genomics, University of Southern California, Los Angeles, CA, USA. davidwcr@usc.edu.

Funding

Targeting breast cancer stem cellsR35CA197585 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WICHA, MAX S. · 2016 to 2022
$6.4M
NCI NIH HHS R35 CA197585
6 · The paper itself

Abstract

backgroundSignificant clinical and research applications are driving large scale adoption of individualized tumor sequencing in cancer in order to identify tumors-specific mutations. When a matched germline sample is available, somatic mutations may be identified using comparative callers. However, matched germline samples are frequently not available such as with archival tissues, which makes it difficult to distinguish somatic from germline variants. While population databases may be used to filter out known germline variants, recent studies have shown private germline variants result in an inflated false positive rate in unmatched tumor samples, and the number germline false positives in an individual may be related to ancestry.

methodsFirst, we examined the relationship between the germline false positives and ancestry. Then we developed and implemented a tumor only caller (LumosVar) that leverages differences in allelic frequency between somatic and germline variants in impure tumors. We used simulated data to systematically examine how copy number alterations, tumor purity, and sequencing depth should affect the sensitivity of our caller. Finally, we evaluated the caller on real data.

resultsWe find the germline false-positive rate is significantly higher for individuals of non-European Ancestry largely due to the limited diversity in public polymorphism databases and due to population-specific characteristics such as admixture or recent expansions. Our Bayesian tumor only caller (LumosVar) is able to greatly reduce false positives from private germline variants, and our sensitivity is similar to predictions based on simulated data.

conclusionsTaken together, our results suggest that studies of individuals of non-European ancestry would most benefit from our approach. However, high sensitivity requires sufficiently impure tumors and adequate sequencing depth. Even in impure tumors, there are copy number alterations that result in germline and somatic variants having similar allele frequencies, limiting the sensitivity of the approach. We believe our approach could greatly improve the analysis of archival samples in a research setting where the normal is not available.

Indexed as

Germ-Line MutationBayes TheoremComputational BiologyDatabases, GeneticDNADNA Copy Number VariationsGene FrequencyHigh-Throughput Nucleotide SequencingHumansNeoplasmsPrecision MedicinePrincipal Component AnalysisDNACancerCopy number alterationsGermline variantNext generation sequencingPrecision medicineSomatic mutationTumor purity

Identifiers

PMID29052513
PMCPMC5649057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.